Tivozanib monotherapy outperforms combination therapy in post-ICI RCC

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2024-11-11 DOI:10.1038/s41585-024-00971-y

Maria Chiara Masone

引用次数: 0

查看原文本刊更多论文

Tivozanib单药治疗ICI后RCC的疗效优于联合疗法

TiNivo-2是一项多中心、随机III期试验，旨在评估血管内皮生长因子受体抑制剂tivozanib单药与免疫检查点抑制剂（ICI）nivolumab联合治疗晚期肾细胞癌（RCC）患者的疗效，这些患者在既往1-2种疗法（包括一种ICI）期间或之后出现进展。单药治疗组患者的无进展生存期（PFS）（7.4个月）高于联合治疗组患者（5.7个月；HR 1.10，95% CI 0.84-1.43；P = 0.49）。这些结果表明，让晚期RCC患者再次接受ICI治疗并不可取，并建议在ICI治疗后将替伏扎尼单药疗法作为一种可行的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.